Detection of AmpC beta-lactamases in Gram-negative bacteria isolated from urine;Detekce β-laktamáz typu AmpC u Gramnegativních bakterií izolovaných z moče

Epidemiologie, Mikrobiologie, Imunologie

Volumn 57, Issue 4, 2008, Pages 141-146

  Cernohorska L ^a   Andrysik T ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

AmpC; ESBL; Gram negative bacteria; Urinary tract infection

Indexed keywords

AMIKACIN; BETA LACTAMASE AMPC; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEPHALOSPORIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; AMPC BETA LACTAMASES; AMPC BETA-LACTAMASES; BACTERIAL PROTEIN; BETA LACTAMASE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DISK DIFFUSION; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; URINALYSIS; URINARY TRACT INFECTION; ENZYMOLOGY; GRAM NEGATIVE BACTERIUM; METABOLISM; MICROBIOLOGY; URINE;

BACTERIAL PROTEINS; BETA-LACTAMASES; GRAM-NEGATIVE BACTERIA; HUMANS; URINARY TRACT INFECTIONS; URINE;

EID: 58749109658     PISSN: 12107913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Alvarez, M., Tran, J. H., Chow, N. et al. Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob Agents Chemother, 2004, 48, 533-537. (Pubitemid 38141713)
2. Ambler, R. P. The structure of β-lactamases. Phil Trans R Soc Lond Biol, 1980, B 289, 321-331.
3. Bradford, P. Extended-spectrum β-lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin Microbiol Rev, 2001, 14, 933-951.
4. Bush, K., Jacoby, G. A., Medeiros, A. A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother, 1995, 39, 1211-1233.
5. Courdon, P. E., Moland, E. S., Thomson, K. S. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates at a Veterans Medical Center. J Clin Microbiol, 2000, 38, 1791-1796.
6. Dunne, W. M., Hardin, D. J. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol, 2005, 43, 5945-5949.
7. Fortineau, N., Poirel, L., Nordmann, P. Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. J Antimicrob Chemother, 2001, 47, 207-210.
8. Giamarellos-Bourboulis, E. J., Papadimitriou, E., Galanakis, N. et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents, 2006, 27, 476-481. (Pubitemid 43767087)
9. Hanson, N. D. AmpC β-lactamases: what do we need to know for the future? J Antimicrob Chemother, 2003, 52, 2-4.
10. Hrabák, J. Klinicky významné β-laktamázy gramnegativních bakterií: AmpC. Epidemiol Mikrobiol Imununol, 2007, 56, 155-165.
11. Hrabák, J., Vaniš, V., Bergerová, T. et al. Průkaz β-laktamáz širokého spektra (ESBL) a typu AmpC u enterobakterií. Zprávy CEM (SZÚ Praha), 2007, 16, 31-36.
12. Chromá, M., Kolář, M., Sauer, P. et al. Molekulárnobiologická analýza ESBL-pozitívnych izolátov Klebsiella pneumoniae od pacientov v intenzívnej starostlivosti. Klinická mikrobiologie a infekční lékařství, 2007, 13, 206-211.
13. Jacoby, G. A, Walsh, K. E., Walker, V. Identification of extended-spectrum, AmpC, and carbapenem-hydrolyzing β-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests. J Clin Microbiol, 2006, 44, 1971-1976.
14. Kolář, M. Klinický význam širokospektrých β-laktamáz a zkušenosti s jejich identifikací v mikrobiologické praxi. Klinická mikrobiologie a infekční lékařství, 2007, 13, 195-205.
15. Kolář, M. Vývoj bakteriální rezistence a nová antimikrobní léčiva. Interní med, 2007, 5, 213-216.
16. Kolář, M., Látal, T., Čermák, P. et al. Prevalence of extended-spectrum β-lactamase-positive Klebsiella pneumoniae isolates in the Czech Republic. Int J Antimicrob Agents, 2006, 28, 49-53.
17. Kolář, M., Urbánek, K., Látal, M. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents, 2001, 17, 357-363. (Pubitemid 32401534)
18. Kolář, M., Urbánek, K., Lochmannová, J. Výchozí zdroje racionální antibiotické léčby bakteriálních infekcí. Prakt Lékáren, 2006, 1, 20-23.
19. Laxminarayan, R. Antibiotic resistance: The unfolding crisis. In: Laxminarayan, R., Malani, A., Howard, D. et al. Extending the cure - Policy responses to the growing threat of antibiotic resistance. Washington D.C., Resources for the Future, 2007, 25-34. ISBN 978-1-933115-57-3.
20. Padilla, E., Alonso, D., Doménech-Sánchez, A. et al. Effect of porins and plasmid-mediated AmpC β-lactamases on the efficacy of β-lactams in rat pneumonia caused by Klebsiella pneumoniae. Antimicrob Agents Chemother, 2006, 50, 2258-2260.
21. Philippon, A., Arlet, G., Jacoby, G. A. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother, 2002, 46, 1-11.
22. Rijavec, M., Budič, M., Mrak, P. et al. Prevalence of COLE1-like plasmids and Colicin K production among uropathogenic Escherichia coli strains and quantification of inhibitory activity of Colicin K. Appl Environ Microbiol, 2007, 73, 1029-1032.
23. Song, W., Moland, E. S., Hanson, N. D. et al. Failure of cefepime therapy in treatment of Klebsiella pneumoniae Bacteremia. J Clin Microbiol, 43, 2005, 43, 4891-4894.
24. Taneja, N., Rao, P., Arora, J. et al. Occurrence of ESBL & Amp-C β-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res, 2008, 127, 85-88.
25. Thomson, K. S. Controversies about Extended-Spectrum and AmpC beta-lactamases. Emerg Inf Dis, 2001, 7, 333-336.
26. Trautner, B. W., Hull, R. A., Darouiche, R.O. Colicins prevent colonization of urinary catheters. J Antimicrob Chemoter, 2005, 56, 413-415.
27. Urbánek, K., Kolář, M., Lovečková, Y. et al. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Therapeut, 2007, 32, 403-408.
28. Urbášková, P. Rezistence bakterií k antibiotikům. Vybrané metody, Trios, 1998.